Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation

A method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) compared to corresponding CADASIL patients with no treatment, wherein the patients with CADASIL have a Notch3 gene mutation resulting in Notch3 aggregation, white matter damage, and reduced cerebral blood flow and modeled by transgenic mice expressing a human Notch3R169C gene, the method comprising:

• obtaining a CEREBROLYSIN® preparation which contains 215.2 mg of CEREBROLYSIN® concentrate,
• wherein the CEREBROLYSIN® concentrate is a mixture of neuropeptides derived from an enzymatic hydrolytic swine brain protein fraction and containing 15% of peptides with a molecular weight of 10,000 or less and approximately 85% of free amino acids including 3.00 mg alanine, 3.00 mg of aspartic acid, 0.06 g of cystine, 4.30 mg of glutamic acid, 1.50 mg of glycine, 1.30 mg of histidine, 2.00 mg of isoleucine, 6.00 mg of leucine, 0.50 mg of methionine, 2.00 mg of phenylalanine, 2.00 mg of proline, 0.30 g of serine, 0.30 g of threonine, 0.50 g of tryptophane and 2.00 mg of tyrosine in 1 ml of the preparation;
• and
• administering the CEREBROLYSIN® preparation to the patients;
• wherein the lifespan of patients with CADASIL is prolonged compared to the lifespan of corresponding CADASIL patients with no treatment.